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disease throughout the world [1]. It is currently considered as the
hepatic manifestation of metabolic syndrome and reﬂects a large
spectrum of liver diseases ranging from rather benign steatosis to
steatohepatitis, cirrhosis, and hepatocellular carcinoma [2,3]. The
pathogenesis of NAFLD involves various hits including lipotoxic-
ity, gut-derived signals such as endotoxin, signals from the innate
immune system such as toll like receptors (TLRs) or pro-inﬂam-
matory cytokines, oxidative stress, and others. There is increasing
evidence that mediators released from the adipose tissue of obese
subjects, such as adipocytokines and classical cytokines, are key
players in NAFLD [4].
NAFLD is frequently associated with morbid obesity which is
often accompanied by chronic inﬂammation. Obesity and associ-
ated insulin resistance are characterized by increased adipose tis-
sue expression of various pro-inﬂammatory mediators such as
tumour necrosis factor-alpha (TNFa), interleukin-1 alpha/beta
(IL-1ab), IL-6, and others [5]. Several IL-1 family (IL-1F) cytokine
members are produced by human adipose tissue in case of obes-
ity. Whereas certain IL-1F members such as IL-1a, IL-1b, or IL-18
are potently pro-inﬂammatory, others such as IL-1 receptor
antagonist (IL-1Ra) or IL-37 (previously named IL-1F7) are anti-
inﬂammatory [6,7]. Processing of IL-1b or IL-18 requires cleavage
by caspase-1, a protease under the control of the inﬂammasome
[8]. Caspase-1 and IL-1b activity in adipose tissue is increased in
both diet-induced and genetically induced animal models of
obesity and mice deﬁcient in caspase-1 or obese animals treated
with a caspase-1 inhibitor are more insulin sensitive [9]. We
recently observed that IL-1b and IL-37 expression was much
higher in subcutaneous/visceral adipose tissue compared to the
liver suggesting that the adipose tissue might reﬂect a major
source of inﬂammatory mediators in morbid obesity [10]. Sys-
temic levels of IL-1Ra are increased in subjects with severe obes-Journal of Hepatology 20
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of pro-inﬂammatory IL-1F members [11].
IL-1F members have been demonstrated to affect insulin/glu-
cose metabolism and regulate metabolic dysfunction. IL-1b is
upregulated in the adipose tissue of obese insulin-resistant mice
and adipocyte-derived IL-1b has been shown to control liver cell
insulin sensitivity [12,13]. IL-1a/ mice have lower fasting glu-
cose and insulin levels and improved insulin sensitivity [5]. IL-
1b is able to reduce insulin receptor substrate-1 expression at a
transcriptional level through ERK dependent and independent
mechanisms [14]. Treatment of type 2 diabetes patients with
recombinant human IL-1Ra improves glycemic control, clearly
highlighting the role of inﬂammation in type 2 diabetes and insu-
lin resistance [15]. In a diet-induced obesity model, treatment
with XOMA 052, a neutralizing anti-IL-1b antibody, improved
insulin sensitivity and led to beta-cell sparing [16]. Elevated IL-
1b, IL-6, or IL-1Ra concentrations predict risk for type 2 diabetes
in humans [17,18]. Type I IL-1 receptor (IL-1RI) may mediate var-
ious aspects of metabolic inﬂammation as free fatty acids, which
are abundantly available in obesity, together with TLR stimula-
tion up-regulate and induce pro-inﬂammatory cytokines, and
IL-1RI engagement results in ampliﬁcation of inﬂammation
[19]. This is of interest, as disruption of this receptor exerted sig-
niﬁcant protection from diet-induced insulin resistance indepen-
dent of obesity [20]. Overall, all these data suggest that IL-1F
members might critically control insulin resistance and meta-
bolic inﬂammation in various obesity-associated disorders.
Kamari and colleagues addressed in this issue of the Journal an
important and long overdue topic, namely the role of IL-1a/b in
steatosis and steatohepatitis [21]. In their study, they used a
diet-induced model of steatosis and steatohepatitis and observed
a considerable increase in the hepatic expression of both IL-1
cytokines. Interestingly, despite demonstrating less inﬂamma-
tion, IL-1a/ mice demonstrated increased hepatic cholesterol
deposition and higher plasma cholesterol levels suggesting that
hepatic fat storage and inﬂammation are not necessarily parallel
events and certain intra-hepatic lipids might exert even protec-
tive, anti-inﬂammatory functions [4]. It also ﬁts with the observa-
tion that in certain instances inﬂammation may precede steatosis
and with the fact that liver steatosis in many instances is a rather
benign condition without subsequent inﬂammation [4]. Both IL-
1a and IL-1b-deﬁcient mice were almost entirely protected from11 vol. 55 j 960–962
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Fig. 1. Intra- and extrahepatic IL-1 cytokine family members may contribute to hepatic steatosis and steatohepatitis. IL-1a and IL-1b are activated and released from
specialized lysosomes and cleaved from precursor proteins by active caspase-1. The inﬂammasome is a highly specialized protein complex that consists of procaspase-1 and
members of the NLR family such as ASC andNLRP3. It is activated by intracellular danger-associatedmolecular patterns (e.g. peptidoglycan) and by endogenous danger signals
such as uric acid andATP.Whereas IL-1a is constitutively expressed by various cell types such as epithelial cells, IL-1b is strongly up-regulated by activatedmacrophages. IL-1a
and IL-1b bind to IL-1RI and then recruit IL-1 receptor accessory protein (IL-1RAcP). Downstream signaling involves recruitment of MyD88 to the Toll-IL-1-receptor (TIR)
domains of IL-1RI and IL-1RAcP. IL-1 receptor associated kinase (IRAK) and IjB kinase ß (IKK-b) are activated. These proximal events ﬁnally result in activation of transcription
factors such as NF-jB. The natural occurring inhibitor IL-1 receptor antagonist (IL-1Ra) binds to and blocks IL-1RI signaling. IL-37, another anti-inﬂammatory IL-1 family
member, suppresses inﬂammation most likely through intracellular interaction with SMAD3. Hepatic and extra-hepatic IL-1 sources might contribute to metabolic liver
inﬂammation. IL-1-type cytokines, especially their pro-inﬂammatory protagonists (IL-1ab), may drive metabolic liver inﬂammation whereas anti-inﬂammatory members of
the IL-1-cytokine family such as IL-1Ra or IL-37 due to decreased production fail to counteract inﬂammatory pathways as observed in nonalcoholic steatohepatitis.
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inﬂammation after diet-induced steatosis, suggesting that these
pro-inﬂammatory IL-1 cytokines might be crucially involved in
the development of liver inﬂammation. Importantly, IL-1a and
IL-1b KO mice demonstrated lower mRNA levels of both inﬂam-
mation and ﬁbrosis-related genes including a signiﬁcant decrease
in TGFb, highlighting the close pathophysiological relationship
between inﬂammation and ﬁbrosis. A key insight of their studies
was also the fact that hepatic and not bone-marrow-derived-IL-
1a/b deﬁciency protected against diet-induced inﬂammation
and ﬁbrosis. The relevance of this data is, however, uncertain as
it has been demonstrated that full reconstitution of Kupffer cells
may occur beyond 9 weeks after bone marrow transplantation
and the authors only allowed a 2 week recovery period after
transplantation before starting the atherogenic diet. Experiments
with hepatocyte- or Kupffer cell/macrophage-speciﬁc IL-1a/b
mice are needed to clearly address these issues. This is of impor-
tance as other extrahepatic cell types such as adipocytes could be
important sources of IL-1a/b in obesity, as suggested by several
studies [10]. The results presented in the Kumari study are in
accordance with another recent report showing that, in a diet-
induced model of obesity, TLR9 controls steatohepatitis via IL-
1b [22]. These authors also found that IL-1b increases lipid accu-
mulation in hepatocytes, regulates inﬂammation, hepatic insulin
resistance, and ﬁbrosis. Overall, these studies together convinc-
ingly show that IL-1a/b are important mediators in metabolic
liver inﬂammation.
In summary, this work by Kumari and colleagues provides
important novel insights on the role of IL-1F cytokine members
in hepatic steatosis and steatohepatitis. It still has to be ﬁgured
out which IL-1 sources are of key relevance in this and other exper-
imental models of NAFLD as extrahepatic sources could critically
contribute to hepatic and overall systemic inﬂammation (Fig. 1).Financial support
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